PF-03049423

Cat. No.: HY-10679A

CAS No.: 402955-58-2

Molecular Formula: $C_{24}H_{32}N_6O_4$.xHCl

Target: Phosphodiesterase (PDE)

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PF-03049423 (Compound PF-5) is a potent and highly selective phosphodiesterase-5A inhibitor with an IC_{50} of about 0.2 nM for rat and human platelet enzyme. PF-03049423 can be used for the research of acute ischaemic stroke[1].	
IC_{50} & Target	PDE5A	rat and human platelet enzyme ~0.2 nM (IC_{50})

In Vivo

PF-03049423 (Compound PF-5) (1-10 mg/kg; s.c.; b.i.d. for 7 days) promotes functional recovery in a rat model of severe stroke induced by permanent middle cerebral artery occlusion[1].

PF-03049423 (1.0 mg/kg b.i.d. or 0.6 mg/kg q.d. for 7 days) improves poststroke sensory–motor behavioral outcome even when the treatment is initiated 24-72 hours after occlusion[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) model[1]
Dosage:	0.1, 1, or 10 mg/kg
Administration:	Subcutaneous injection, b.i.d. for 7 days
Result:	Improved functional recovery at 1 mg/kg and 10 mg/kg.

REFERENCES

[1]. Menniti FS, et al. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. J Pharmacol Exp Ther. 2009 Dec;331(3):842-50.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA